Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study

被引：5
|
作者：
Ramalingam, Suresh S. [1 ]
Saka, Hideo [2 ]
Ahn, Myung-Ju [3 ]
Yu, Helena [4 ]
Horn, Leora [5 ]
Hida, Toyoaki [6 ]
Cantarini, Mireille [7 ]
Verheijen, Remy [7 ]
Wessen, Jonathan [7 ]
Oxnard, Geoffrey [8 ]
Ohe, Yuichiro [9 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Natl Hosp Org, Nagoya Med Ctr, Nagoya, Aichi, Japan
[3] Samsung Med Ctr, Seoul, South Korea
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] Aichi Canc Ctr, Nagoya, Aichi, Japan
[7] Astrazeneca, Global Med Dev, Cambridge, England
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
[9] Natl Canc Ctr, Tokyo, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT034
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Wang, Yan
    Wu, Ying
    Ling, Yan
    Liu, Ke
    Zang, Yuan-Sheng
    LUNG CANCER, 2022, 170 : 91 - 97
  • [22] First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
    Xu, Qinghua
    Liu, Hui
    Meng, Shuyan
    Jiang, Tao
    Li, Xuefei
    Liang, Shixiong
    Ren, Shengxiang
    Zhou, Caicun
    JOURNAL OF CANCER, 2019, 10 (02): : 522 - 529
  • [23] Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment
    Lu, S.
    Cheng, Y.
    Wu, L.
    Fang, J.
    Li, B.
    Han, L.
    Zhang, Y.
    Pan, H.
    Wang, Z.
    Sun, Y.
    Ye, F.
    Hu, Y.
    Yu, W.
    Zhou, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S649 - S649
  • [24] Osimertinib (OSI) vs Standard of Care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
    Bischoff, H. G.
    Rueckert, A.
    Reinmuth, N.
    Grohe, C.
    Bohnet, S.
    zum Bueschenfelde, C. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 187 - 187
  • [25] Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
    Liam, C. K.
    Ahmad, A. Rozila
    Hsia, T.
    Li, J. Y.
    Le, X.
    Heymach, J.
    Yang, J. C.
    Soo, R.
    Zhang, Y.
    Kim, S.
    Shin, S. W.
    Johne, A.
    Karachaliou, N.
    Bruns, R.
    Ellers-Lenz, B.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1118 - S1119
  • [26] Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study
    Akamatsu, Hiroaki
    Koh, Yasuhiro
    Ozawa, Yuichi
    Fujimoto, Daichi
    Hata, Akito
    Katakami, Nobuyuki
    Tomii, Keisuke
    Shimokawa, Toshio
    Yamamoto, Nobuyuki
    CLINICAL LUNG CANCER, 2018, 19 (06) : E871 - E874
  • [27] Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC
    Zhu, Y.
    Chen, Y.
    Han, S.
    Ying, X.
    Sun, X.
    Xu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S502 - S502
  • [28] TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
    Oxnard, G. R.
    Yang, J. C. -H.
    Yu, H.
    Kim, S. -W.
    Saka, H.
    Horn, L.
    Goto, K.
    Ohe, Y.
    Mann, H.
    Thress, K. S.
    Frigault, M. M.
    Vishwanathan, K.
    Ghiorghiu, D.
    Ramalingam, S. S.
    Ahn, M. -J.
    ANNALS OF ONCOLOGY, 2020, 31 (04) : 507 - 516
  • [29] SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification
    Yu, Y.
    Yang, N.
    Zhang, Y.
    Zhang, H.
    Li, M.
    Yu, Q.
    Zhou, J.
    Hu, X.
    Fang, J.
    Zhao, H.
    Feng, J.
    Li, L.
    Shu, Y.
    Wang, X.
    Sun, M.
    Zhang, J.
    Li, M.
    Ren, Y.
    Lu, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1553 - S1553
  • [30] SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET driven (MET plus ), locally advanced or metastatic non small cell lung cancer (NSCLC), following disease progression on osimertinib.
    Oxnard, Geoffrey R.
    Cantarini, Mireille
    Frewer, Paul
    Hawkins, George
    Peters, Jane
    Howarth, Paul
    Ahmed, Ghada F.
    Sahota, Tarjinder
    Hartmaier, Ryan
    Li-Sucholeiki, Xiaocheng
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345